Please assess the completion status of the following clinical trial:

Trial Title: Trial for the Treatment of Acute Hepatitis C for 8 Weeks With Sofosbuvir/Velpatasvir

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Willing and able to provide written informed consent~2. Male or female, age \> 18 years~3. HCV RNA \> 10\^3 IU/mL at screening~4. Confirmation of acute HCV infection documented by either:~   1. Documented seroconversion to HCV antibody (anti-HCV) positivity within the 4 months preceding screening~  2. Documented conversion to HCV RNA positivity within the 4 months preceding screening~  3. or known or suspected exposure to HCV within the 4 months preceding screening with 10 times elevated serum ALT level at screening or 4 month preceding screening without evidence of confounding liver disorders~5. Body mass index (BMI) ≥18 kg/m2~6. Subjects must have the following laboratory parameters at screening:~   1. INR ≤ 1.5 x ULN unless subject has known hemophilia or is stable on an anticoagulant regimen affecting INR~  2. HbA1c ≤ 10%~  3. Creatinine clearance (CLcr) ≥ 30 mL/min, as calculated by the Cockcroft-Gault equation (using actual body weight)~7. A negative serum pregnancy test is required for female subjects (unless surgically sterile or women ≥ 54 years of age with cessation for 24 ≥ months of previously occurring menses). Complete abstinence from intercourse. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) is not permitted.~   Or~   Consistent and correct use of 1 of the following methods of birth control listed below, in addition to a male partner who correctly uses a condom, from the date of Screening until the end of follow up:~  * intrauterine device (IUD) with a failure rate of \< 1% per year~  * female barrier method: cervical cap or diaphragm with spermicidal agent~  * tubal sterilization~  * vasectomy in male partner~  * hormone-containing contraceptive:~     * implants of levonorgestrel~    * injectable progesterone~    * oral contraceptives (either combined or progesterone only)~    * contraceptive vaginal ring~    * transdermal contraceptive patch~8. Subject must be able to comply with the dosing instructions for study drug administration and be able to complete the study schedule of assessments~Exclusion Criteria:~1. Subject has been treated with any investigational drug or device within 42 days of the Screening visit~2. Co-Infection with HIV~3. Clinically-significant illness (other than HCV) or any other major medical disorder that, in the opinion of the investigator, may interfere with subject treatment, assessment or compliance with the protocol.~4. Solid organ transplantation~5. Gastrointestinal disorder or post-operative condition that could interfere with the absorption of the study drug (for example, gastric bypass or severe ulcerative colitis).~6. Clinical signs of hepatic decompensation (i.e., clinical ascites, encephalopathy or variceal hemorrhage).~7. Difficulty with blood collection and/or poor venous access for the purposes of phlebotomy.~8. Psychiatric hospitalization, suicide attempt, and/or a period of disability as a result of their psychiatric illness within the last 2 years. Subjects with psychiatric illness that is well-controlled on a stable treatment regimen for at least 12 months prior to screening or has not required medication in the last 12 months may be included.~9. Significant drug allergy (such as anaphylaxis or hepatotoxicity).~10. Pregnant or nursing female~11. Clinically-relevant drug or alcohol abuse that significantly impairs patient compliance. Uncontrolled users of intravenous drugs will not be permitted to enroll in the study.~12. Clinical relevant (not controlled) liver disease of a non-HCV etiology (e.g., hemochromatosis, autoimmune hepatitis, alcoholic liver disease, Wilson's disease, α1 antitrypsin deficiency, cholangitis)~13. Use of any prohibited concomitant medications within 21 days before the Baseline/Day 1 visit. The use of amiodarone is prohibited from 60 days prior to Day 1 through the end of treatment;~14. Known hypersensitivity to SOF/VEL or formulation excipients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sofosbuvir and Velpatasvir (Type: EXPERIMENTAL): SOF/VEL FDC film-coated tablet, oral, SOF 400 mg/VEL 100 mg daily, 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).